← All trials
NCT04543110
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2020
- Primary completion
- Feb 28, 2022
- Completion date
- Nov 30, 2024
- First posted
- Sep 9, 2020
- Last posted
- Sep 9, 2020
- Enrollment
- 25
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OttawaLead sponsor
- AstraZenecaCollaborator
- University of OttawaOverall official - principal investigator
- University of AlbertaCollaborator
- University of AlbertaOverall official - principal investigator
- University of Western OntarioCollaborator
- Ozmosis Research Inc.Collaborator
- Hamilton Health Sciences CorporationCollaborator
- Ontario Institute for Cancer ResearchCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.